or with one high-risk feature) breast cancer. Herceptin can be used several different ways: As part of a treatment regimen including doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; With docetaxel and carboplatin; As a single agent following multi-modality anthracycline-based therapy. Herceptin in combination with paclitaxel is approved for the first-line treatment of HER2-overexpressing metastatic breast cancer. Herceptin as a single agent is approved for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease. High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3. What important safety information should I know about Herceptin? HERCEPTIN TREATMENT CAN RESULT IN HEART PROBLEMS, INCLUDING THOSE WITHOUT SYMPTOMS (REDUCED HEART FUNCTION) AND THOSE WITH SYMPTOMS (CONGESTIVE HEART FAILURE). THE RISK AND SERIOUSNESS OF THESE HEART PROBLEMS WERE HIGHEST IN PEOPLE WHO RECEIVED BOTH HERCEPTIN AND A CERTAIN TYPE OF CHEMOTHERAPY (ANTHRACYCLINE). YOUR DOCTOR WILL STOP OR STRONGLY CONSIDER STOPPING HERCEPTIN IF YOU HAVE A SIGNIFICANT DROP IN YOUR HEART FUNCTION. You should be monitored for decreased heart function before your first dose of Herceptin, and frequently during the time you are receiving Herceptin and after your last dose of Herceptin. If you must permanently or temporarily stop Herceptin due to heart problems, you should be monitored more frequently. In one study with Herceptin and certain types of chemotherapy, an inadequate blood supply to the heart occurred. SOME PATIENTS HAVE HAD SERIOUS INFUSION REACTIONS AND LUNG PROBLEMS; FATAL INFUSION REACTI